Artificial Intelligence-assisted Colonoscopy With or Without Endocuff Vision

Sponsor
E-DA Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05863208
Collaborator
Chung Shan Medical University (Other)
1,000
1
3
44
22.7

Study Details

Study Description

Brief Summary

Adenoma detection rate (ADR) is considered the single most important quality measure in colonoscopy and a higher ADR can reduce the risk of interval colorectal cancer (CRC). Several kinds of new endoscopes and accessories have been accessed to investigate the abilities of improving the ADR. Artificial intelligence (AI) and Endocuff vision are promising new devices to improve the ADR. However, the effect of combining AI and Endocuff vision on ADR remains unclear. The aim of this prospective randomized study is to compare the ADR of AI plus Endocuff vision, AI alone and standard colonoscopy examination.

Condition or Disease Intervention/Treatment Phase
  • Device: Artificial intelligence
  • Device: Endocuff vision
  • Device: High-definition endoscope
N/A

Detailed Description

This is a prospective single-blinded randomized controlled trial of three different types of colonoscopy examinations by 1:1:1 ratio. We use EndoAim AI (ASUS, Taiwan) and Endocuff vision (Olympus, UK) assisted colonoscopy in the first group. We use AI assisted colonoscopy in the 2nd group. We use standard colonoscopy in the 3rd group.

Eligible patients are older than 40 years old and receive colonoscopy for either symptomatic or screening/surveillance. All endoscopists should receive training on EndoAim AI systems and Endocuff vision. During the procedure, experienced endoscopists use high-definition endoscopes (EVIS-EXERA 290 video system, Olympus Optical, Aizu, Japan) under white light and insert to the cecum in the three different groups. The cecal intubation is confirmed by the identification of ileocecal valve and appendiceal orifice.

The Boston Bowel Preparation Scale is used for grading the bowel preparation quality. The size (compared with biopsy forceps), location and morphology of polyps are recorded by the independent endoscopist. All polyps ae removed by either biopsy or polypectomy. The insertion and withdrawal time are measured. The time of the polypectomy site is not included in the withdrawal time.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1000 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Diagnostic
Official Title:
Comparison of The Adenoma Detection Rate Between Artificial Intelligence-assisted Colonoscopy With or Without Endocuff Vision and Standard Colonscopy: A Randomized Controlled Study
Actual Study Start Date :
May 2, 2023
Anticipated Primary Completion Date :
Dec 31, 2025
Anticipated Study Completion Date :
Dec 31, 2026

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Artificial Intelligence-assisted Colonoscopy with Endocuff Vision

Use artificial intelligence-assisted colonoscopy with Endocuff Vision

Device: Artificial intelligence
ASUS EndoAim AI Endoscopy System (ASUS, Taiwan) is used to help the detection of colon adenoma

Device: Endocuff vision
Endocuff vision (Olympus, UK) is used to help the detection of colon adenoma

Device: High-definition endoscope
High-definition endoscope (EVIS-EXERA 290 video system, Olympus Optical, Aizu, Japan) is used under white light for the detection of colon adenoma

Active Comparator: Artificial Intelligence-assisted Colonoscopy

Use artificial intelligence-assisted colonoscopy alone

Device: Artificial intelligence
ASUS EndoAim AI Endoscopy System (ASUS, Taiwan) is used to help the detection of colon adenoma

Device: High-definition endoscope
High-definition endoscope (EVIS-EXERA 290 video system, Olympus Optical, Aizu, Japan) is used under white light for the detection of colon adenoma

Sham Comparator: Standard colonoscopy

Use standard colonoscopy without artificial intelligence-assisted colonoscopy or Endocuff Vision

Device: High-definition endoscope
High-definition endoscope (EVIS-EXERA 290 video system, Olympus Optical, Aizu, Japan) is used under white light for the detection of colon adenoma

Outcome Measures

Primary Outcome Measures

  1. Adenoma detection rate [One month after colonoscopy]

    The proportion of patients with at least one adenomas

Secondary Outcome Measures

  1. Polyp detection rate [One month after colonoscopy]

    The proportion of patients with at least one polyp

  2. Sessile serrated adenoma detection rate [One month after colonoscopy]

    The proportion of patients with at least one sessile serrated adenoma

  3. Sessile serrated polyps detection rate [One month after colonoscopy]

    The proportion of patients with at least one sessile serrated polyp

  4. Advanced adenoma detection rate [One month after colonoscopy]

    The proportion of patients with at least one advanced adenoma

  5. Mean number of polyp per patient [One month after colonoscopy]

    The mean number of polyp per patient

  6. Mean number of adenoma per patient [One month after colonoscopy]

    The mean number of adenoma per patient

  7. Total number of polyp or adenoma per patient [One month after colonoscopy]

    The total number of polyp or adenoma per patient

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Patients over 20 years old are undergoing outpatient sedative colonoscopy in the E-Da Hospital, E-Da cancer Hospital and Chung Shan Medical University Hospital in Taiwan

Exclusion Criteria:
  • A prior history of of inflammatory bowel disease, colorectal cancer, previous bowel resection, Peutz-Jeghers syndrome, familial adenomatous polyposis or other polyposis syndromes

  • Bleeding tendency

  • For scheduled endoscopic treatment

Contacts and Locations

Locations

Site City State Country Postal Code
1 E-DA Hospital Kaohsiung City Taiwan 82445

Sponsors and Collaborators

  • E-DA Hospital
  • Chung Shan Medical University

Investigators

  • Study Chair: Ying Nan Tsai, MD, Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, Kaohsiung, Taiwan

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
E-DA Hospital
ClinicalTrials.gov Identifier:
NCT05863208
Other Study ID Numbers:
  • EMRP53109N
First Posted:
May 17, 2023
Last Update Posted:
May 17, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 17, 2023